What is HC Wainwright’s Forecast for Erasca FY2027 Earnings?

Erasca, Inc. (NASDAQ:ERAS) – Stock analysts at HC Wainwright reduced their FY2027 earnings per share estimates for shares of Erasca in a research report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.50) per share for the year, down from their prior estimate of ($0.40). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca’s FY2028 earnings at ($0.55) EPS, FY2029 earnings at ($0.55) EPS and FY2030 earnings at ($0.37) EPS.

Erasca (NASDAQ:ERAS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11).

Several other research firms also recently weighed in on ERAS. Piper Sandler lifted their target price on shares of Erasca from $5.00 to $11.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Erasca in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research note on Thursday, January 22nd. Stifel Nicolaus set a $10.00 target price on Erasca in a report on Monday, January 12th. Finally, Mizuho initiated coverage on Erasca in a report on Tuesday. They set an “outperform” rating and a $16.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.22.

Erasca Trading Up 1.8%

NASDAQ ERAS opened at $10.31 on Wednesday. Erasca has a 1 year low of $1.01 and a 1 year high of $10.71. The company has a market cap of $3.19 billion, a PE ratio of -22.91 and a beta of 1.15. The stock’s 50-day moving average price is $5.20 and its two-hundred day moving average price is $3.07.

Hedge Funds Weigh In On Erasca

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its position in Erasca by 594.8% in the first quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock worth $543,000 after acquiring an additional 339,177 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Erasca by 130.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 36,362 shares of the company’s stock valued at $46,000 after purchasing an additional 20,558 shares during the last quarter. Savant Capital LLC bought a new stake in Erasca in the second quarter worth $87,000. Los Angeles Capital Management LLC bought a new stake in Erasca in the second quarter worth $45,000. Finally, Geode Capital Management LLC increased its position in Erasca by 1.6% during the second quarter. Geode Capital Management LLC now owns 4,835,642 shares of the company’s stock worth $6,143,000 after buying an additional 77,790 shares during the last quarter. Institutional investors own 67.78% of the company’s stock.

Insiders Place Their Bets

In other news, General Counsel Ebun Garner sold 120,000 shares of Erasca stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $5.59, for a total transaction of $670,800.00. Following the completion of the sale, the general counsel directly owned 25,076 shares in the company, valued at $140,174.84. The trade was a 82.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 14.40% of the stock is currently owned by insiders.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.